ReviewCurrent opinion in HIV and AIDS2026
The female microbiome in HIV prevention, pathogenesis, and treatment.
Review in Current opinion in HIV and AIDS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Metabolic Calibration of Female Immune Plasticity: From X-Linked Vulnerability to Precision Metabotyping.Biology · 2026Review
- Suppressor of cytokine signaling (SOCS) proteins in human retroviral infections.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purpose of reviewTo summarize the relationship of vaginal and gut microbiomes with HIV transmission, pathogenesis, and treatment, focusing on women's health. RECENT
findingsBacterial vaginosis (i.e., vaginal microbiome dysbiosis) is a well established risk factor for HIV acquisition, and recent research focused on molecular mechanisms and biomarkers for HIV acquisition related to vaginal microbiota. Recent clinical trials reported on probiotics to treat bacterial vaginosis with the goal of HIV prevention; however, durability of treatment response remains sub-optimal. The vaginal microbiome may impact efficacy of preexposure prophylaxis (PrEP) and antiretroviral therapy (ART) in vaginal tissue, with recent literature examining vaginal microbiota and long-acting PrEP vaginal rings. Some research also suggests effects of PrEP or ART initiation on the vaginal microbiome. Regarding the gut microbiome, associations with HIV status may differ more by sexual practices than biological sex, and sex-specific roles of gut microbiota in HIV pathogenesis and treatment are unknown. Interactions of the gut microbiome with estrogens could underlie a role of gut microbiota in health of women with HIV. SUMMARY: The vaginal microbiome remains an important factor in HIV acquisition, prevention, and treatment in women. The gut microbiome has roles in HIV pathogenesis and treatment, but women-specific effects are unclear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.